Abstract

Arya Narayanan*, Sumeena Beevi S., Dhanya Dharman and Shaiju S. Dharan

ABSTRACT

Tuberculosis (TB) is a highly contagious bacterial infection. Although it can occur almost anywhere in the body, the most common site of infection for TB is the lungs. Among the first-line combination therapy medications Isoniazid (INH), Rifampicin (RMP), Pyrazinamide (PZA) and Ethambutol (EMB). INH, RMP, and PZA are hepatotoxic since they are metabolized primarily by the liver. Hepatotoxicity brought on by anti-tuberculosis medications occurs frequently. When jaundice appeared more than 6 weeks after the start of ATT (Anti- Tuberculosis Therapy), death from ATT-induced hepatotoxicity was more likely. Usually, following recovery from ATT-induced hepatitis, anti-tuberculosis medications with a risk of causing hepatitis can be safely reintroduced. Here we report a case of 52-year-old female patient who was admitted in hospital due to ATT induced hepatitis.